World leader in antimicrobial technology selects clinivation team to lead clinical development of award-winning infection control system.
Framingham, MA, October 26, 2001 – clinivation, Inc. announced today that The Dial Corporation (NYS: DL) has selected clinivation to provide turnkey, outsourced clinical development solutions and services for its award-winning clinical infection control system.
“The Dial Corporation is clearly a world leader in antimicrobial technology, and we are honored to have been selected to lead the clinical development of this award-winning infection control system,” said Joseph Kozikowski, M.D., Chairman and Chief Technology Officer of clinivation. Obed Cepeda, M.D., who joined clinivation from The Yale University School of Medicine, and Fabio Mariano, who joined clinivation from The Massachusetts General Hospital and Harvard University, will manage clinical operations for this project.
Dial’s research and development team was awarded the 2001 American Chemical Society Industrial Innovation Award for their breakthrough antimicrobial technology that significantly outperforms competitive products across a number of important performance endpoints.
Clinical development will be conducted in conjunction with clinivation’s Health Innovations resource alliance that provides expedited access to the 15,000-member base of AmeriNet, the nation’s largest GPO.
About The Dial Corporation
The Dial Corporation, headquartered in Scottsdale, Arizona, is one of America’s leading manufacturers of consumer products, including Dial soaps, Purex laundry detergents, Renuzit air fresheners, Armour Star canned meats, and the Sarah Michaels and Freeman Cosmetics personal care brands. Dial products have been in the marketplace for more than 100 years.
For more information about The Dial Corporation, visit the Company’s Web site at www.dialcorp.com
